| [1] |
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1):120. DOI: 10.1186/s13045-018-0664-7.
doi: 10.1186/s13045-018-0664-7
|
| [2] |
蒋中秀, 崔国元, 张晓晔. 安罗替尼治疗晚期非小细胞肺癌的疗效与安全性的Meta分析[J]. 现代肿瘤医学, 2021, 29(2):242-248. DOI: 10.3969/j.issn.1672-4992.2021.02.013.
doi: 10.3969/j.issn.1672-4992.2021.02.013
|
| [3] |
谢婷婷, 王伟兰. 盐酸安罗替尼致急性心肌梗死1例[J]. 中国药物应用与监测, 2020, 17(1):62-63.
|
| [4] |
徐伟芳, 张媛慧, 朱建伟. 贝伐珠单抗联合化疗致脑梗死及下肢静脉血栓形成1例[J]. 临床肿瘤学杂志, 2014, 19(4):383-384.
|
| [5] |
Zhang D, Zhang X, Zhao C. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review[J]. Onco Targets Ther, 2016, 9:3695-3704. DOI: 10.2147/OTT.S103735.
doi: 10.2147/OTT.S103735
|
| [6] |
Greenwald AC, Licht T, Kumar S, et al. VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells[J]. J Exp Med, 2019, 216(1):215-230. DOI: 10.1084/jem.20180752.
doi: 10.1084/jem.20180752
|
